Additional Supporting Information may be found in the online version of this article.

IJC_24866_sm_supfig1.tif2632KSupplementary Figure S1. BEX2 and BEX1 expression using Real-Time PCR in cell lines. (a) BEX2 expression folds in breast cancer cell lines relative to that of MCF-7 using RT-PCR. Error Bars: ± 2SEM. (b) BEX1 expression was assessed in breast cancer cell lines MCF-7, MDA-MB-231, T-47D, BT-474, Sum190, MDA-MB-361, SK-BR-3, and MDA-MB-453; prostate cancer cell line LNCap; and glioma cell lines U251MG and U87MG. Expression values are shown as: (40-CT) and a value of 0 means no detected expression.
IJC_24866_sm_supfig2.tif2094KSupplementary Figure S2. Real Time-PCR showing BEX2-knock down in breast cancer cell lines. BEX2-knock down efficiencies are shown for siRNA duplex 1/2 (Dup1/2), duplex 3/4 (Dup3/4), and duplex 5/6 (Dup 5/6) in MCF-7, MDA-MB-231, and T-47D cell lines. Expression of BEX2 after knock-down was assessed relative to non-targeting siRNA control and fold changes are shown for each duplex in each cell line.
IJC_24866_sm_supfig3.tif319KSupplementary Figure S3. The effect of BEX2 on ceramide pro-apoptotic response. (a) Percentage of apoptosis in MCF-7 cells after BEX2-knock down (KD) and treatment with ceramide. Ceramide treatment was carried out at 3 μM, 7 μM, and 10 μM concentrations overnight and apoptosis was measured using Hoechst assay. Non-targeting siRNA was used as a control. (b) Percentage of apoptosis in MDA-MB-231 cells as described in A. (c) Percentage of apoptosis in T-47D cells as described in A. (d) Hoechst staining to show the apoptotic cells in MDA-MB-231 cells after BEX2-KD and ceramide treatment at 3 μM. All error bars indicate: ± 2SEM.
IJC_24866_sm_supfig4.tif208KSupplementary Figure S4. BEX2-Knock Down and doxorubicin treatment. Histograms show the percentage of apoptosis using Annexin V-FITC assay inMDA-MB-231 cells. Cells were transfected with the control siRNA (a) or BEX2-siRNA (b) followed by doxorubicin treatment at 200 nM overnight.
IJC_24866_sm_supfig5.tif1426KSupplementary Figure S5. The effect of BEX2 down-regulation on p21. CDKN1A transcriptional change after BEX2 Knock-Down. RT-PCR was carried out in MCF-7 and MDA-MB-231 cells after transfections with either control-siRNA (control) or BEX2-siRNA. CDKN1A expression fold to control group is demonstrated for both cell lines. *, p < 0.03 is for the difference between knock-down and control groups in MDA-MB-231 cells. Error Bars: ± 2SEM.
IJC_24866_sm_supTable-1.doc28KSupplementary Table 1. Percentage of p65 nuclear staining.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.